Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV

Vaccine

Volumn 23, Issue 46-47, 2005, Pages 5306-5320

  Zhan, Xiaoyan ^a   Martin, Louis N ^b   Slobod, Karen S ^a,c   Coleclough, Chris ^a,c   Lockey, Timothy D ^a   Brown, Scott A ^a   Stambas, John ^a,d   Bonsignori, Mattia ^a,e   Sealy, Robert E ^a   Blanchard, James L ^b   Hurwitz, Julia L ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Envelope cocktail; HIV 1 vaccine; Non human primate; Pathogenic SHIV

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; CD4 ANTIGEN; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; ASSAY; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RETROVIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS RECOMBINANT; VIRUS TITRATION;

AIDS VACCINES; ANIMALS; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV-1; IMMUNITY, CELLULAR; MACACA MULATTA; NEUTRALIZATION TESTS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINATION; VIRAL LOAD;

EID: 27644527759     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.07.008     Document Type: Article

References (78)

1. N. Walker, K.A. Stanecki, and T. Brown Methods and procedures for estimating HIV/AIDS and its impact: the UNAIDS/WHO estimates for the end of 2001 AIDS 17 2003 2215 2225
2. S.-L. Hu, K. Abrams, and G.N. Barber Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160 Science 255 1992 456 459
3. P.W. Berman, T.J. Gregory, and L. Riddle Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 Nature 345 1990 622 625
4. P. Polacino, V. Stallard, and J.E. Klaniecki Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen J Virol 73 1999 618 630
5. B.S. Graham, M.J. McElrath, and R.I. Connor Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group J Infect Dis 177 1998 310 319
6. R.E. Biagini, S.A. Schlottmann, and D.L. Sammons Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides Clin Diagn Lab Immunol 10 2003 744 750
7. M.D. Daniel, F. Kirchhoff, S.C. Czajak, P.K. Sehgal, and R.C. Desrosiers Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene Science 258 1992 1938 1941
8. J.E. Clements, R.C. Montelaro, and M.C. Zink Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus J Virol 69 1995 2737 2744
9. M.J. Gonzales, E. Delwart, and S.Y. Rhee Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation J Infect Dis 188 2003 397 405
10. R.M. Ruprecht, F. Ferrantelli, M. Kitabwalla, W. Xu, and H.M. McClure Antibody protection: passive immunization of neonates against oral AIDS virus challenge Vaccine 21 2003 3370 3373
11. T. Wrin, L. Crawford, L. Sawyer, P. Weber, H.W. Sheppard, and C.V. Hanson Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus J Acquir Immune Defic Syndr 7 1994 211 219
12. N.L. Davis, I.J. Caley, and K.W. Brown Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles J Virol 74 2000 371 378
13. C. Buckner, L.G. Gines, and C.J. Saunders Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV Virology 320 2004 167 180
14. R.R. Amara, F. Villinger, and J.D. Altman Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine Vaccine 20 2002 1949 1955
15. N.L. Letvin, Y. Huang, and B.K. Chakrabarti Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys J Virol 78 2004 7490 7497
16. M.T. Maggiorella, S. Baroncelli, and Z. Michelini Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys Vaccine 22 2004 3258 3269
17. G.R. Campbell, E. Pasquier, and J. Watkins The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis J Biol Chem 279 2004 48197 48204
18. H.W. Sheppard Inactivated- or killed-virus HIV/AIDS vaccines Curr Drug Targets Infect Disord 5 2005 131 141
19. S.D. Rencher, K.S. Slobod, D. Dawson, T.D. Lockey, and J.L. Hurwitz Does the key to a successful HIV vaccine lie among the envelope sequences of infected individuals? Aids Res Hum Retroviruses 11 1995 1131 1133
20. S.D. Rencher, and J.L. Hurwitz Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3 and non-V3-specific antibodies J Acquir Immune Defic Syndr 16 1997 69 73
21. J. Weber, E.M. Fenyo, S. Beddows, P. Kaleebu, and A. Bjorndal Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO network for HIV isolation and characterization J Virol 70 1996 7827 7832
22. T.E. Caver, T.D. Lockey, R.V. Srinivas, R.G. Webster, and J.L. Hurwitz A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation Vaccine 17 1999 1567 1572
23. Richmond JFL, F. Mustafa, and S. Lu Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting Virology 230 1997 265 274
24. S.D. Rencher, T.D. Lockey, R.V. Srinivas, R.J. Owens, and J.L. Hurwitz Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants Vaccine 15 1997 265 272
25. J. Stambas, S.A. Brown, and A. Gutierrez Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy Vaccine 23 2005 2454 2464
26. X. Zhan, K.S. Slobod, S. Surman, S.A. Brown, C. Coleclough, and J.L. Hurwitz Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells Vaccine 22 2004 1206 1213
27. S. Surman, T.D. Lockey, and K.S. Slobod Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing Proc Natl Acad Sci USA 98 2001 4587 4592
28. S.A. Brown, J. Stambas, and X. Zhan Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity J Immunol 171 2003 4140 4148
29. K.W. Ryan, R.J. Owens, and J.L. Hurwitz Preparation and use of vaccinia virus vectors for HIV protein expression and immunization I. Lefkovits Immunology methods manual 1st ed. 1997 Academic Press London, England 1995 2015
30. P. Earl, and B. Moss Expression of proteins in mammalian cells using vaccinia viral vectors F.M. Ausubel R. Brent R.E. Kingston D.D. Moore J.G. Seidman J.A. Smith Current protocols in molecular biology 2nd ed. 1997 John Wiley and Sons Inc. USA 16151 161810
31. S. Hallenberger, S.P. Tucker, R.J. Owens, H.B. Bernstein, and R.W. Compans Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein Virology 193 1993 510 514
32. R.J. Owens, C. Burke, and J.K. Rose Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity J Virol 68 1994 570 574
33. K.A. Reimann, J.T. Li, and R. Veazey A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys J Virol 70 1996 6922 6928
34. K.S. Slobod, C. Coleclough, and M. Bonsignori HIV vaccine rationale, design and testing Curr HIV Res 3 2005 103 112
35. T.D. Lockey, K.S. Slobod, and T.E. Caver Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees Immunol Res 21 2000 7 21
36. J.L. Hurwitz, K.S. Slobod, T.D. Lockey, S. Wang, T.H. Chou, and S. Lu Application of the polyvalent approach to HIV-1 vaccine development Curr Drug Targets Infect Disord 5 2005 143 156
37. K.S. Slobod, T.D. Lockey, and N. Howlett Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1 Eur J Clin Microbiol Infect Dis 23 2004 106 110
38. E. Hammarlund, M.W. Lewis, and S.G. Hansen Duration of antiviral immunity after smallpox vaccination Nat Med 9 2003 1131 1137
39. R. Bures, A. Gaitan, and T. Zhu Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 AIDS Res Hum Retroviruses 16 2000 2019 2035
40. K.C. Cheng, G.L. Smith, and B. Moss Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus J Virol 60 1986 337 344
41. S.M. Hsieh, S.C. Pan, S.Y. Chen, P.F. Huang, and S.C. Chang Age distribution for T cell reactivity to vaccinia virus in a healthy population Clin Infect Dis 38 2004 86 89
42. C. Fogg, S. Lustig, J.C. Whitbeck, R.J. Eisenberg, G.H. Cohen, and B. Moss Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions J Virol 78 2004 10230 10237
43. L. Hyland, M. Sangster, R. Sealy, and C. Coleclough Respiratory virus infection of mice provokes a permanent humoral immune response J Virol 68 1994 6083 6086
44. M.K. Slifka, R. Antia, J.K. Whitmire, and R. Ahmed Humoral immunity due to long-lived plasma cells Immunity 8 1998 363 372
45. C. Coleclough, R. Sealy, S. Surman, D.R. Marshall, and J.L. Hurwitz Respiratory vaccination of mice against influenza virus: dissection of T cell and B cell priming functions Scand J Immunol 62 Suppl. 1 2005 73 83
46. K.K. Van Rompay, C.J. Berardi, and S. Dillard-Telm Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection J Infect Dis 177 1998 1247 1259
47. S.P. Layne, M.J. Merges, J.L. Spouge, M. Dembo, and P.L. Nara Blocking of human immunodeficiency virus infection depends on cell density and viral stock age J Virol 65 1991 3293 3300
48. P.L. Nara, and G. Lin HIV-1: the confounding variables of virus neutralization Curr Drug Targets Infect Disord 5 2005 157 170
49. X. Zhan, K.S. Slobod, and S. Surman Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein 34 J Virol 77 2003 4231 4236
50. N. Hozumi, and S. Tonegawa Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions Proc Natl Acad Sci USA 73 1976 3628 3632
51. J. Cohen AIDS vaccines. HIV dodges one-two punch Science 305 2004 1545 1547
52. P.J. Lehner, and P. Cresswell Recent developments in MHC-class-I-mediated antigen presentation Curr Opin Immunol 16 2004 82 89
53. S.A. Hammond, R.P. Johnson, and S.A. Kalams An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL J Immunol 154 1995 6140 6156
54. P. Guermonprez, J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena Antigen presentation and T cell stimulation by dendritic cells Annu Rev Immunol 20 2002 621 667
55. R.L. Ferris, C. Hall, and N.V. Sipsas Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization J Immunol 162 1999 1324 1332
56. S.A. Brown, J.L. Hurwitz, X. Zhan, P.C. Doherty, and K.S. Slobod CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection? Curr Drug Targets Infect Disord 5 2005 113 119
57. D.H. Barouch, J. Kunstman, and J. Glowczwskie Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys J Virol 77 2003 7367 7375
58. A.M. Prince, H. Reesink, and D. Pascual Prevention of HIV infection by passive immunization with HIV immunoglobulin Aids Res Hum Retroviruses 7 1991 971 973
59. L. Zhang, R.M. Ribeiro, and J.R. Mascola Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination J Virol 78 2004 5520 5522
60. J.R. Mascola, M.G. Lewis, and G. Stiegler Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies J Virol 73 1999 4009 4018
61. N.L. Letvin, D.C. Montefiori, and Y. Yasutomi Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination Proc Natl Acad Sci USA 94 1997 9378 9383
62. R.R. Amara, J.M. Smith, and S.I. Staprans Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine J Virol 76 2002 6138 6146
63. Z. Si, M. Cayabyab, and J. Sodroski Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys J Virol 75 2001 4208 4218
64. M. Cayabyab, G.B. Karlsson, and B.A. Etemad-Moghadam Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2) J Virol 73 1999 976 984
65. R.C. Tan, J.M. Harouse, A. Gettie, and C. Cheng-Mayer In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein J Med Primatol 28 1999 164 168
66. M. Cayabyab, D. Rohne, and G. Pollakis Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate AIDS Res Hum Retroviruses 20 2004 27 40
67. K.A. Reimann, J.T. Li, and G. Voss An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys J Virol 70 1996 3198 3206
68. G.B. Karlsson, M. Halloran, and J. Li Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys J Virol 71 1997 4218 4225
69. S.L. Hu Non-human primate models for AIDS vaccine research Curr Drug Targets Infect Disord 5 2005 193 201
70. J.R. Mascola, M.G. Lewis, and T.C. VanCott Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies J Virol 77 2003 10348 10356
71. D.H. Barouch, J. Kunstman, and M.J. Kuroda Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes Nature 415 2002 335 339
72. I.M. Belyakov, Z. Hel, and B. Kelsall Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques 38 Nat Med 7 2001 1320 1326
73. T.U. Vogel, M.R. Reynolds, and D.H. Fuller Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239 J Virol 77 2003 13348 13360
74. N.F. Rose, P.A. Marx, and A. Luckay An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants Cell 106 2001 539 549
75. W.-P. Kong, Y. Huang, Z-Y. Yang, B.K. Chakrabarti, Z. Moodie, and G.J. Nabel Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines J Virol 77 2003 12764 12772
76. P.W. Berman, A.M. Gray, and T. Wrin Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers J Infect Dis 176 1997 384 397
77. C.L. Byington, M.H. Samore, and G.J. Stoddard Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups Clin Infect Dis 41 2005 21 29
78. G.S. Goldman Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage Vaccine 21 2003 4243 4249